title: [Circulating endothelial cells in the peripheral blood of advanced NSCLC patients].
abstract: OBJECTIVE
  To investigate the changes and clinical value of circulating endothelial cells (CEC) in the peripheral blood of advanced NSCLC patient.
  
  
  METHODS
  Sixty-seven advanced NSCLC patients were randomly divided into either the treatment group with NP plus endostatin or control group with NP alone. Level of CEC and cytokeratin (CK) in the peripheral blood were measured by flow cytometry.
  
  
  RESULTS
  The response rate and benefit rate was 44.4%, 80.0% in the treatment group, and 27.3%, 50.0% in the control group, respectively (P = 0.176 and P = 0.012). Time to tumor progression (TTP) was 146.7 days in the treatment group and 91.1 days in the control group (P = 0.061). However, when the cut-off of TTP was defined as > 170 days, there was a significant difference between two groups (cut-off = 170, P = 0.034; cut-off = 180, P = 0.009). The number of CEC decreased by 0.29 +/- 0.47 in the treatment group and by 0.01 +/- 0.43 in the control group (P = 0.033). The correlation between CEC and CK was found to be positive either before (r = 0.381, P = 0.013) or after the treatment (r = 0.450, P = 0.004).
  
  
  CONCLUSIONS
  Chemotherapy combined with endostatin is superior to chemotherapy alone in the treatment of NSCLC. CEC, as a biomarker, may be useful in predicting the efficacy of the combined treatment.
authors: Department of Medical Oncology, Tianjin Cancer Institute & Hospital Tianjin Medical University, Tianjin 300060, China.
authors: Chun
authors: C
authors: Huang
authors: Kai
authors: K
authors: Li
authors: Xi-Yin
authors: XY
authors: Wei
authors: Rui-Fang
authors: RF
authors: Niu
authors: Yan
authors: Y
authors: Sun
authors: Jin-Wan
authors: JW
authors: Wang
authors: Yun-Zhong
authors: YZ
authors: Zhu
authors: Li-Yan
authors: LY
authors: Xu
authors: Xiao-Qing
authors: XQ
authors: Liu
authors: Hong-Jun
authors: HJ
authors: Gao
authors: Jing-Min
authors: JM
authors: Zhou
authors: Xiu-Wen
authors: XW
authors: Wang
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000188:drug therapy / Q000473:pathology*; D002452:Cell Count; D002945:Cisplatin / Q000008:administration & dosage; D043169:Endostatins / Q000008:administration & dosage; D042783:Endothelial Cells / Q000473:pathology*; D004730:Endothelium, Vascular / Q000473:pathology; D005260:Female; D005434:Flow Cytometry; D005500:Follow-Up Studies; D006801:Humans; D007633:Keratins / Q000097:blood; D008175:Lung Neoplasms / Q000097:blood / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009360:Neoplastic Cells, Circulating / Q000473:pathology*; D012074:Remission Induction; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine
chemical_list: D043169:Endostatins; D014747:Vinblastine; D007633:Keratins; D002945:Cisplatin; D000077235:Vinorelbine